Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
| العنوان: | Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 |
|---|---|
| المؤلفون: | Ming Yi, Suxia Luo, Shengnan Yu, Linping Xu, Shuang Qin, Kongming Wu |
| المصدر: | Molecular Cancer, Vol 18, Iss 1, Pp 1-14 (2019) Molecular Cancer |
| بيانات النشر: | BMC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, medicine.drug_class, TIGIT, T-Lymphocytes, T cell, medicine.medical_treatment, TIM-3, Programmed Cell Death 1 Receptor, VISTA, Review, Lymphocyte Activation, Monoclonal antibody, lcsh:RC254-282, Immunomodulation, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immune system, LAG-3, Neoplasms, Biomarkers, Tumor, medicine, Animals, Humans, CTLA-4 Antigen, Molecular Targeted Therapy, BTLA, Clinical Trials as Topic, biology, Immunotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immune checkpoint, Treatment Outcome, 030104 developmental biology, medicine.anatomical_structure, B7-H3, Oncology, CTLA-4, 030220 oncology & carcinogenesis, biology.protein, Cancer research, Molecular Medicine, Antibody |
| الوصف: | The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type of cancers. Despite some ICIs have manifested compelling clinical effectiveness in certain tumor types, the majority of patients still showed de novo or adaptive resistance. At present, the overall efficiency of immune checkpoint therapy remains unsatisfactory. Exploring additional immune checkpoint molecules is a hot research topic. Recent studies have identified several new immune checkpoint targets, like lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), and so on. The investigations about these molecules have generated promising results in preclinical studies and/or clinical trials. In this review, we discussed the structure and expression of these newly-characterized immune checkpoints molecules, presented the current progress and understanding of them. Moreover, we summarized the clinical data pertinent to these recent immune checkpoint molecules as well as their application prospects. |
| اللغة: | English |
| تدمد: | 1476-4598 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ab764b0272cb7de85bf00ba3474375Test http://link.springer.com/article/10.1186/s12943-019-1091-2Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....62ab764b0272cb7de85bf00ba3474375 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14764598 |
|---|